Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Blastic plasmacytoid dendritic cell neoplasm
- Focus Adverse reactions
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Jul 2018 Planned initiation date changed from 30 Apr 2018 to 30 Aug 2018.
- 05 Apr 2018 New trial record